Vinpocetine-ESCOM - instructions for use, doses, side effects, contraindications

Means, improves brain metabolism, increasing glucose and oxygen by brain tissue. Improves the stabilitythe ability of brain cells to hypoxia, facilitating the transport of oxygen and substrates of energy supply to tissues (due to a decrease in the affinity for erythrocytes, increased absorption and metabolism of glucose, switching it to an energetically more advantageous aerobic direction). It promotes the accumulation in the tissues of cyclic adenosine monophosphate and adenosine triphosphate (inhibition of Ca²⁺ - dependent phosphodiesterase and stimulation of adenylate cyclase), an increase in the content catecholamine tissues the brain. Stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.

The vasodilatory effect is related to the direct relaxing influence on the smooth muscles of vessels predominantly of the brain. Vinpocetine does not cause the phenomenon of "stealing", primarily enhances the blood supply of the ischemic region of the brain, while not changing the blood supply of intact areas.

Improves microcirculation in the brain due to a decrease in platelet aggregation, decrease in blood viscosity, increase in the deformability of erythrocytes.

Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant effect on the parameters of the systemic circulation (blood pressure, heart rate, minute volume).

Pharmacokinetics:

Therapeutic concentration with parenteral introduction into plasma - 10-20 ng / ml, the volume of distribution - 5.3 l / kg. Easily penetrates through gistogematicheskie barriers (including the blood-brain barrier). Penetrates into breast milk (0.25% within the first hour), through the placental barrier. T_1/2- 4.74-5 h. It is excreted by the kidneys and intestines in the ratio of 3: 2.

Indications:

Neurology: as a symptomatic tool for various forms of cerebral circulatory insufficiency (ischemic stroke, the recovery stage of hemorrhagic stroke, the consequences of a stroke; transient ischemic attack; vascular dementia, vertebrobasilar insufficiency; atherosclerosis of cerebral vessels; posttraumatic and hypertensive encephalopathy). Ophthalmology: chronic vascular diseases of the choroid and retina (including occlusion of the central artery or vein of the retina).

Perceptive hearing loss, Meniere's disease, idiopathic noise in ears.

Contraindications:

Hypersensitivity, acute phase of hemorrhagic stroke, severe ischemic heart disease, severe heart rhythm disturbances, pregnancy, lactation period, age up to 18 years.

For dosage formscontaining sorbitol (optional): fructose intolerance, 1,6-diphosphatase deficiency.

Dosing and Administration:

Intravenously drip (the rate of infusion should not beto exceed 80 cap / min). The initial daily dose is 20 mg (dissolved in 0.5-1 L 0.9 % solution of sodium chloride or solutions containing dextrose). The average daily dose at a body weight of 70 kg-50 mg. With good tolerance for 2-3 days, the dose is raised to the maximum - 1 mg / kg / day. The course of treatment is 10-14 days. After achieving the improvement, they switch to taking the drug inside.

Side effects:

From the side of the cardiovascular system: changes in the electrocardiogram (segment depression ST, elongation Q-T interval); tachycardia, extrasystole (cause-and-effect relationship not established), lability of blood pressure (more often decrease).

From the central nervous system: sleep disturbance (insomnia, increased drowsiness); dizziness, headache, general weakness (may be a manifestation of the underlying disease).

From the digestive system: dry mouth, nausea, heartburn.

Other: skin allergic reactions, increased sweating, skin hyperemia, phlebitis with intravenous administration.

Interaction:

A solution of vinpocetine for injection is pharmaceutically incompatible with heparin, solutionscontaining an amino acid.

It is possible to intensify the hypotensive effect with simultaneous application with methyldopa (blood pressure control is necessary).

Despite the lack of data confirming the possibility of interaction, it is advisable to use caution when used simultaneously with central medicine, antiarrhythmics and anticoagulants.

Special instructions:

When introducing solutions of vinpocetine containing sorbitol, in patients with diabetes should monitor blood glucose. In the case of the original elongation Q-T interval, as well as with simultaneous use with drugs that extend Q-T interval, during the treatment with vinpocetine, periodic electrocardiographic monitoring is necessary.

Effect on the ability to drive transp. cf. and fur:Do not use during work drivers of vehicles and people whose profession is associated with increased concentration of attention.

Form release / dosage:Concentrate for the preparation of solution for infusions 5 mg / ml.

Packaging:

For 2 ml in ampoules of light-protective neutral glass or neutral glass.

For 10 ampoules, together with instructions for medical use and a scarifier, the ampullum is placed in a cardboard bundle with cardboard partitions, or 5 or 10 ampoules are placed in a contour cell box made of a polyvinyl chloride film.

When using ampoules with a notch or a fracture ring, the scarifier is not inserted. For 1 or 2 contour cell pack of polyvinylchloride film together with instructions for medical use put in a pack of cardboard.

Storage conditions:In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:2 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-000662

Date of registration:28.09.2011

Expiration Date:28.09.2016

Date of cancellation:2017-06-14

The owner of the registration certificate:ESKOM NPK, OAO ESKOM NPK, OAO Russia

Manufacturer: & nbsp

ESKOM NPK, OAO Russia

Information update date: & nbsp14.06.2017

Illustrated instructions

Instructions

Vinpocetine-ESCOM (Vinpocetine-ESKOM)